Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Yi‐Long Wu, Chong‐Rui Xu et al.|Cancer Cell|2021Cited by 232
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi‐Yang Maggie Liu, Yi‐Long Wu, Bing-Fei Xu et al.|EClinicalMedicine|2023Cited by 11
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiangtao Cheng, Jin‐Ji Yang, Yihui Yao et al.|Lung Cancer|2020Cited by 9